HR Execs on the Move


 
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eledon.com
  • 19900 MacArthur Boulevard Suite 550
    Irvine, CA USA 92612
  • Phone: 949.238.8090

Executives

Name Title Contact Details

Similar Companies

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

EMR Innovations

EMR Innovations is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PharmaPix

PharmaPix is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TBS Dental

We create premium products to make dentistry more efficient. Over the years, TBS has designed and developed a number of contemporary, state-of-the-art instruments with the intent of modernization.

Beam Therapeutics

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other